Despite many setbacks, it ultimately succeeded in developing and getting approval for an orphan drug used to treat a deadly lung disease, IPF.
The protagonist, InterMune's CEO, Dan Welch, joined the company in 2003 and has directed InterMune through multiple divestitures, leadership changes, clinical trial disappointments, numerous tactical pivots, and ultimately the sale of the company. The capacity as well as resilience is at the center of this case study.
The story concentrates on leadership changes, and strategic, cultural and choices made by Welch, the Board and also the leadership team throughout the tenure of Welch. Especially, InterMune's tactical focus sharpened on a few indications, evolved the Board and the leadership team, and orchestrated a grassroots initiative to re-invent InterMune's core values and ethnic pillars.
Resilience at InterMune A Journey Through the Valley of the Shadow of Death case study solution
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
PUBLICATION DATE: June 10, 2015 PRODUCT #: B5838-PDF-ENG
Related Case Solutions & Analyses:
Wheeling Cardiology Associates
Engaging Values in International Business Practice
Loafing in the 21st Century: Enhanced Opportunities–and Remedies–for Withholding Job Effort in the New Workplace
Life Stories of Recent MBAs: Values and Ethical Challenges
Designing Impact Evaluations: Assessing Jamaicas PATH Program
Centurion Media: Doing the Right Thing
The Good Commissioner (A)
Premier Inc.
ABC and Food Lion: Case Study
Ethics and Internal Controls: A Case of Entertainment Expenses
